Vaxcyte, Inc. PCVX Proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs
Proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept pcvx:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts.
The official record: Vaxcyte, Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs?
- Vaxcyte, Inc. (PCVX) reported proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs of $0 in Q4 2025.
- How has Vaxcyte, Inc.'s proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs changed year-over-year?
- Vaxcyte, Inc.'s proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs decreased by 100.0% year-over-year, from $559.93M to $0.
- What does proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs mean?
- This measures the total cash inflows generated from the sale of common equity or pre-funded warrants through follow-on public offerings, net of underwriting and issuance costs. It reflects the company's ability to raise capital from public markets to fund research, development, or operational expansion. This is a primary indicator of external financing activity and dilution risk for existing shareholders.